EMA Authorised: Fruzaqla (fruquintinib) — Takeda Pharmaceuticals International AG Ireland

View source ↗

Summary

Authorised medicinal product Fruzaqla (fruquintinib) for colorectal neoplasms in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• FRUZAQLA (fruquintinib)

Snippet

Status: Authorised. Therapeutic area: Colorectal Neoplasms. MAH: Takeda Pharmaceuticals International AG Ireland. Decision date: 12/05/2026